Allogene Therapeutics Inc (ALLO)
3.55
-0.25
(-6.58%)
USD |
NASDAQ |
Apr 15, 16:00
3.55
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Revenue (TTM): 0.095M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.095M |
| September 30, 2023 | 0.099M |
| June 30, 2023 | 0.105M |
| March 31, 2023 | 0.147M |
| December 31, 2022 | 0.156M |
| Date | Value |
|---|---|
| September 30, 2022 | 75.85M |
| June 30, 2022 | 75.85M |
| March 31, 2022 | 75.80M |
| December 31, 2021 | 114.09M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.095M
Minimum
Dec 2023
114.09M
Maximum
Dec 2021
38.02M
Average
0.156M
Median
Dec 2022
Revenue (TTM) Benchmarks
| Agenus Inc | 156.31M |
| ANI Pharmaceuticals Inc | 486.82M |
| Vaxart Inc | 9.104M |
| aTyr Pharma Inc | -- |
| PAVmed Inc | 2.452M |